Jazz Pharmaceuticals, Inc. (JAZZ)

baselineace (64.65) Submitted: 11/17/2009 4:49:20 PM : Start Price: $7.79 JAZZ Score: -8.11

P/E of 1.12 + Insider buying at Goldman Sachs

manucastle (68.11) Submitted: 11/12/2009 12:10:22 PM : Start Price: $6.91 JAZZ Score: +1.84

I have re-purchased JAZZ :-

http://finance.yahoo.com/q?s=jazz&.yficrumb=yIQAwlz5SoW

Industry: biotechnology & drugs
EPS = -3.48
EPS EST 1yr = -0.557 2yr = 0.073
EPS EST Q1 = -0.050 Q2 = 0.020
PE = na Industry 15.2
PB = na Industry 2.7
PS = 2.07 Industry 3.5
P/CF = na industry 13.6
P/FCF = na Industry 13.7
Yield 0.0 Industry 0.0
Gross profit margin = 86.2 Industry 51.0
Operating margin = -81.3 Industry -42.3
Net Profit Margin = -99.8 Industry -42.0
ROA = -74.8 Industry -52.3
ROE = 134.7 Industry -14.7
Insider ownership = 60.3
Greenblatt ROC = 651.20
Greenblatt Earnings Yield = 0.00
PosFCF generic % free cash flow yield -32.27%***
LT debt less than Gross Income = Fail
Passes 13 of 17 of Mike Klein's metrics
MaxPrice = 24.24 Discount 71%**
Metrics from qtr ending 6/30/2009
Caps rank 1
http://caps.fool.com/Ticker/JAZZ.aspx
MC score 247

All good enough for my money. I only suggest stocks that I own !

(See posts 388/584/665/760/1051/1807/2213/3546/3755/4046/4208/4225/4345/4573/4818/5241/5242/5310/5461/5579/
5169/7651 on 'Investment Analysis Clubs / Dynamic Value Investing ' board for extra due diligence applied ). **MaxPrice is a generic version of Mike Klein's Maxprice and ROC and Earnings yields are generic versions of Greenblatt's metrics. *** PosFCF generic % free cash flow yield taken from AAII and posts 5248 and 5253

See 'Investment Analysis Clubs / Dynamic Value Investing' board and my CAPS profile for further excellent companies selling at a discount to Maxprice with excellent current metrics. CAPS only shows my selections over 100Mill (unfortunately due to restricted lower market cap applied by MF CAPS).

As stated on the 'Investment Analysis Clubs /Dynamic Value Investing' board my aim is to obtain up to 50% returns p.a. as Buffett stated he could obtain (3 times) recently. A very difficult task but you can follow along with my buys and sells on my CAPS page, where I put my money where my mouth is . If I perform well I hope you can benefit. If not , feel free to ignore my comments. CAPS allows each and everyone of us to be clinically judged on our stock picking abilities over the LONG TERM.

Please always do your own due diligence before investing.

Manucastle :o)

cashsage (87.44) Submitted: 11/7/2009 1:45:18 PM : Start Price: $6.96 JAZZ Score: +0.37

JAZZ has a too high valuation compared to its sales potential. It is also one of the most loss making companies. Its stock price may be more than halved.

Hook5351 (< 20) Submitted: 9/8/2009 8:33:08 PM : Start Price: $8.96 JAZZ Score: -28.29

Rumor has it JAZZ may taken over buy Forrest Labs

Snowpro1 (< 20) Submitted: 9/6/2009 1:08:04 PM : Start Price: $8.96 JAZZ Score: -28.29

Insiders /Phase 111

michaeltbryant (< 20) Submitted: 9/5/2009 10:44:35 PM : Start Price: $8.96 JAZZ Score: -28.29

Hm...............insider bought 1.5 million shares.

yaodao (< 20) Submitted: 8/28/2009 12:17:09 PM : Start Price: $6.98 JAZZ Score: -6.33

Japanese Candlestick

keithtarbi (25.89) Submitted: 8/24/2009 10:55:15 AM : Start Price: $6.25 JAZZ Score: +6.58

Great stock..new drug offering!!!

mlb1232000 (21.93) Submitted: 8/12/2009 8:50:15 AM : Start Price: $7.82 JAZZ Score: -20.54

Earnings report last night. Good report.

LexTNZorro (74.71) Submitted: 6/19/2009 10:36:49 PM : Start Price: $3.39 JAZZ Score: +86.74

http://seekingalpha.com/article/143384-fda-calendar-updates-transdel-javelin-jazz-par-pharma?source=feed

TSIF (98.47) Submitted: 6/18/2009 3:22:40 PM : Start Price: $3.13 JAZZ Score: +103.43

JAZZ Pharmaceuticals stopped playing the blues after Phase III data was released indicating it'ssodium oxybate (JZP-6) showed a statistically significant reduction in fibromyalgia pain. Since the drug is already marketed to treat narcolepsy (a chronic sleep disorder), the safety concern of the two major issues for approval, (safety and affectivity) should be minimal. JAZZ soard as high as $4.85 as is typical on drug stocks with good news lately. The pullback to the low $3's in my opinion is a gift. Yes drug stocks are highly volitile. Funding, results, approvals, all cause gyrations. It is becoming harder to buy a drug between Phase III and FDA approval/disapproval with a decent risk reward as speculators abound. I think JAZZ has a good valuation. To have only been in business since 2003, Jazz's portfolio of neurology and psychiatry drugs/candidates has some great potential. I'm JAZZ'd up on JAZZ.

geodawg2000 (< 20) Submitted: 6/16/2009 10:41:38 PM : Start Price: $3.77 JAZZ Score: -65.75

this was too quick of a run. Especially only after a trail run.